FDA will pull GSK diabetes drugs in risk-mitigation strategy

05/18/2011 | Bloomberg · Los Angeles Times (tiered subscription model)

The FDA announced that GlaxoSmithKline's diabetes medicine Avandia, or rosiglitazone, as well as combination drugs Avandamet and Avandaryl will no longer be sold at retail pharmacies beginning Nov. 18. The withdrawal is part of an FDA strategy restricting access to Avandia because of heart risk. "Health care providers and patients must be enrolled in the Avandia-rosiglitazone Medicines Access Program in order to prescribe and receive rosiglitazone medicines," the agency said.

View Full Article in:

Bloomberg · Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR